Study title: Stark B et al, Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report, Cancer. 2000 Jan 1;88(1):205-16
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Neoplasms [C04] | |||||
Brands: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: ETOPOSIDE | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |